Dear Editor,
Cancer cells need to reprogram fatty acid (FA) metabolism to promote cell growth and survival through exogenous lipid uptake and FA biosynthesis catalyzed by the multidomain containing mammalian FA synthase (FASN).1,2 The bidirectional relationships of oncogenic signaling and de novo lipogenesis (DNL) suggest that FASN is a druggable target in many cancers. Although FASN inhibitors including Fasnall, GSK2194069, IPI-9119, orlistat, TVB-2640, TVB-3166, and TVB-3664 have shown promise in preclinical cancer models or early-phase clinical trials, none have been approved for the treatment of cancers (Supplementary Table S1).3 Here we report a unique inhibitor targeting the ketosynthase (KS) domain of FASN, which shows superior cytotoxicity and selectivity over orlistat and TVB-3166, as well as strong antitumor effects in both non-small cell lung cancer (NSCLC) and melanoma mouse xenografts.
Platensimycin was originally discovered as a bacterial FabF/B inhibitor by competition with their substrate malonyl-acyl carrier protein (ACP), while later it showed potent inhibitory activity (IC50 = 0.3 μM) against mammalian FASN.4 To discover selective FASN inhibitors against NSCLC, we screened a focused library of platensimycin derivatives against KRAS-positive A549 and NCI-H1299 cells (Fig. 1a and Supplementary Figs. S1–S6). Several 6-aryl platensimycin derivatives showed inhibitory activity from 54.3% to 91.2% against both cell lines (Supplementary Fig. S7), among which 6p exhibited an IC50 of 16.95 ± 1.96 μM, superior to TVB-3166, orlistat, and cerulenin (Fig. 1b and Supplementary Table S2). The selectivity of 6p may protect the less fatty acid-dependent normal cells upon its exposure. The 6p-treated cells showed notable morphological changes, reduced colony number and sizes either alone or in combination with cis-platinum (CDDP) (Fig. 1c and Supplementary Fig. S8a–b), as well as G2/M cell cycle arrest and apoptosis (Supplementary Fig. S8c–e). Furthermore, 6p appreciably inhibited cell migration and invasion (Fig. 1d and Supplementary Fig. S9). In contrast, 6-(4-bromophenyl)-platensic acid and platensimycin showed no cytotoxicity, suggesting that 3-amino-2,4-dihydroxybenzoic acid (ADHBA) and 6-(4-bromophenyl) group are critical for the cytotoxicity of 6p (Supplementary Fig. S10).
To study if 6p interacts with FASN, it was docked to the KS-malonyltransferase (MAT) didomain of FASN, showing hydrogen bonding interactions of ADHBA with H293 and H331 of KS active site (Fig. 1e and Supplementary Fig. S10c). The molecular dynamic simulation revealed that 6p likely bound to KS-MAT more tightly than platensimycin, with 26.76 kcal/mol less non-bond energy (Fig. 1f and Supplementary Fig. S10). The IC50 values of 6p were reduced by 9- or 4-fold in A549 and NCI-H1299 cells cultured with 1% fetal bovine serum to decrease free FAs uptake, confirming the target specificity of 6p against FASN (Fig. 1g and Supplementary Fig. S11b). Surprisingly, the cell growth inhibition could only be partially rescued by the addition of oleate and palmitate, while exogenous palmitate could rescue cell inhibition by orlistat (Fig. 1h and Supplementary Fig. S11).
FASN is highly expressed in A549 and NCI-H1299 cells, and 6p markedly decreased its expression in a dose-dependent manner (Figs. 1i, j and Supplementary Fig. S12). Orlistat treatment only modestly affected FASN expression, while platensimycin had no obvious effects (Supplementary Fig. S13). Immunofluorescence confirmed that 6p crucially decreased the expression of FASN in the cytoplasm of treated NCI-H1299 cells (Fig. 1k). In contrast, Fasnall or TVB-3166/IPI-9119 treatment led to either no change of FASN expression or significantly induced FASN expression, suggesting that 6p may bypass the FASN-overexpression compensatory mechanism.3 RNA sequencing of 6p-treated NCI-H1299 cells showed that 6p significantly downregulated the expression of key genes involved in lipogenesis, cell cycle, DAN replication, mitosis, and steroid biosynthesis, and upregulated genes in apoptosis, ferroptosis, and amino acid metabolism pathways, in comparison with the control group (Fig. 1l and Supplementary Figs. S14–S15). Subsequent RT-qPCR confirmed that 6p treatment resulted in pronounced downregulation of FASN, sterol regulatory element-binding transcription factor 1 (SREBF1), stearoyl-CoA desaturase-1 (SCD1), and acetyl-CoA carboxylase (ACC) in both A549 and NCI-H1299 cells (Fig. 1m). Immunoblotting experiments showed that 6p dose-dependently decreased the expression of pSREBP-1c and mSREBP-1c in A549 and NCI-H1299 cells (Fig. 1n). In contrast, previous reports suggest that TVB-3166-treated tumor cells increased the expression of most of these genes.3 Since SREBP-1, SCD1, and ACC are all key nodes in DNL, their global down-regulation by 6p highlights its unique antiproliferative potential.
Although the oncogenic signal transduction pathways including PI3K-AKT-mTOR regulate fatty acid biosynthesis, and oncogene KRAS activates FASN, 6p treatment resulted in marked reduction of p-AKT and p-mTOR in the treated A549 and NCI-H1299 cells, since FA metabolism also regulates oncogenic signaling (Fig. 1o and Supplementary Fig. S16).5 The 6p- or TVB-3166-treated NCI-H1299 cells had distinct lipid profiles in the HR-ESI-MS/MS analysis, exemplified by their different lipid signature in the top ten lipid metabolites, while their overall lipid composition and distribution was similar (Supplementary Figs. S17–S19 and Supplementary Table S4). The decreased total abundance of saturated and monounsaturated fatty acids include C16:0 and C18:1 in various glycerolipids and glycerophospholipids, especially triglycerides as the main forms for fatty acid storage and transport, consistent with the inhibition of FASN by 6p (Fig. 1p, Supplementary Figs. S20–S22 and Supplementary Tables S5–S7). The significant accumulation of stearic acid (C18:0) may be caused by the down-regulation of SCD1 (Fig. 1m). In addition, polyunsaturated fatty acid and odd-numbered fatty-acyl chains were dramatically increased because of their exogenous uptake, highlighting the metabolic flexibility of these cancer cells.
We further explored the antitumor effect of 6p using the A549 xenograft mouse model. Subcutaneous injection of 6p or in combination with CDDP resulted in slower tumor growth and lower tumor weight than the control group (Fig. 1q, r and Supplementary Fig. S23). HE and Ki67 staining demonstrated that 6p effectively inhibited tumor growth with no obvious toxicity (Supplementary Fig. S23). Immuno-staining and immuno-blotting assay showed that 6p also decreased FASN and p-AKT levels in the treated tumors (Fig. 1s and Supplementary Fig. S23e). Although FASN is also highly expressed in melanoma, few FASN inhibitors except orlistat have been evaluated in a mouse melanoma model. Since 6p significantly inhibited clone formation and decreased FASN expression in A375 cell lines (Supplementary Fig. S24), we next evaluated its antitumor effects in A375 xenografts. 6p effectively inhibited melanoma growth without obvious toxicity, compared to orlistat and platensimycin (Fig. 1t, u). Although intravenous administration of 6p and platensimycin exhibited no systematic toxicity, they did not reduce tumor volume in A375-derived xenografts, which suggests the need to further optimize 6p scaffold (Supplementary Fig. S25 and Supplementary Table S8).
In conclusion, a specific FASN inhibitor 6p was discovered to have strong antitumor effects in two tumor xenografts through rewiring FA metabolism (Fig. 1v).1,2 Compound 6p may compete with malony-ACP to inhibit KS-catalyzed Claisen condensation and block the remaining catalytic steps of other domains in FASN. The reduced production of palmitate may affect membrane architecture including lipid rafts3 and thus compromise activities of receptor tyrosine kinases,5 leading to the inhibition of PI3K-AKT-mTOR signaling and subsequent downregulation of SREBP-1, SCD1, and ACC. These lipogenic enzymes are all therapeutically explored to treat cancer and their inhibition can be achieved by 6p treatment alone. This study not only revealed a KS-domain specific FASN inhibitor with great translational potential, but also discovered that targeting a single enzyme FASN could lead to the global inhibition of dysregulated DNL, a nearly-universal feature of cancer metabolism.
Data availability
The online version of this article contains supplementary material, which is available to authorized users.
References
Röhrig, F. & Schulze, A. The multifaceted roles of fatty acid synthesis in cancer. Nat. Rev. Cancer 16, 732–749 (2016).
Koundouros, N. & Poulogiannis, G. Reprogramming of fatty acid metabolism in cancer. Br. J. Cancer 122, 4–22 (2020).
Ventura, R. et al. Inhibition of de novo palmitate synthesis by fatty acid synthase induces apoptosis in tumor cells by remodeling cell membranes, inhibiting signaling pathways, and reprogramming gene expression. EBioMedicine 2, 808–824 (2015).
Wu, M. et al. Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes. PNAS 108, 5378–5383 (2011).
Gouw, A. M. et al. Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma. PNAS 114, 4300–4305 (2017).
Acknowledgements
This work was supported in parts by the National Natural Science Foundation of China (82173688), the Chinese Ministry of Education 111 Project (BP0820034), The science and technology innovation Program of Hunan Province (2021RC4067), and Hunan Provincial Natural Science Foundation of China (2021JJ30791), the Hunan Provincial Innovation Foundation for Postgraduate (NO. 2019zzts332).
Author information
Authors and Affiliations
Contributions
D-F.C., Y-W.D., and Y.H. designed the research and wrote the paper. D-F.C. and M.S. performed cytotoxicy screening experiments; J.Y. and Y-C.D. provided the reagents; D-F.C. performed gene expression, cellular analyses, and animal experiments with the help of X-Q.F., Y.X., and E-H.B. All authors have read and approved the article.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics
All animal studies were approved by the Institutional Animal Care and Treatment Committee of Central South University.
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Cao, D., Yang, J., Deng, Y. et al. Discovery of a mammalian FASN inhibitor against xenografts of non-small cell lung cancer and melanoma. Sig Transduct Target Ther 7, 273 (2022). https://doi.org/10.1038/s41392-022-01099-4
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41392-022-01099-4